Biogen (BIIB) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BIIB Analyst Ratings

Moderate Buy

16 Buy

6 Hold

1 Sell

Based on 23 analysts giving stock ratings to

Biogen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BIIB Stock 12 Month Forecast

Average Price Target

CHF202.08

▼(-8.97% Downside)

Based on 23 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is CHF202.08 with a high forecast of CHF255.60 and a low forecast of CHF144.29. The average price target represents a -8.97% change from the last price of CHF222.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"143":"CHF143","256":"CHF256","171.25":"CHF171.3","199.5":"CHF199.5","227.75":"CHF227.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":255.5952697,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF255.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":202.07766777454543,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF202.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":144.28765225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF144.29</span>\n  </div></div>","useHTML":true}}],"tickPositions":[143,171.25,199.5,227.75,256],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,222,224.5842515153846,227.16850303076922,229.75275454615385,232.33700606153846,234.92125757692307,237.50550909230768,240.0897606076923,242.67401212307692,245.25826363846153,247.84251515384614,250.42676666923077,253.01101818461538,{"y":255.5952697,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,222,220.46751290573425,218.93502581146853,217.4025387172028,215.87005162293707,214.33756452867132,212.80507743440558,211.27259034013986,209.7401032458741,208.20761615160836,206.67512905734264,205.1426419630769,203.61015486881118,{"y":202.07766777454543,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,222,216.02212709615384,210.0442541923077,204.06638128846154,198.08850838461538,192.11063548076925,186.13276257692308,180.15488967307692,174.17701676923076,168.19914386538463,162.22127096153847,156.24339805769233,150.26552515384617,{"y":144.28765225,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":222,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF255.60

Average Price TargetCHF202.08

Lowest Price TargetCHF144.29

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jason Zemansky

Bank of America Securities

CHF180.57→CHF201.18

Hold

-9.38%

Downside

Reiterated

10/22/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (NASDAQ: BIIB), Elevance Health (NYSE: ELV) and Myriad Genetics (NASDAQ: MYGN)

Phil Nadeau

TD Cowen

CHF185.51→CHF206.13

Buy

-7.15%

Downside

Reiterated

10/21/26

Biogen price target raised to $250 from $225 at TD CowenBiogen price target raised to $250 from $225 at TD Cowen

Mohit Bansal

Wells Fargo

CHF206.13→CHF255.6

Buy

15.13%

Upside

Reiterated

10/20/26

Wells Fargo Reaffirms Their Buy Rating on Biogen (BIIB)

Laura Chico

Wedbush

CHF174.79

Hold

-21.26%

Downside

Reiterated

10/19/26

Wedbush Remains a Hold on Biogen (BIIB)

Jeffrey Walch

Bernstein

CHF194.58

Buy

-12.35%

Downside

Reiterated

10/19/26

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), AbbVie (NYSE: ABBV) and Marker Therapeutics (NASDAQ: MRKR)

David Amsellem

Piper Sandler

CHF202

Buy

-9.01%

Downside

Reiterated

10/12/26

Piper Sandler Keeps Their Buy Rating on Biogen (BIIB)

Geoff Meacham

Citi

CHF177.27

Hold

-20.15%

Downside

Reiterated

10/12/26

Citi Remains a Hold on Biogen (BIIB)

Evan Seigerman

BMO Capital

CHF171.5→CHF181.39

Hold

-18.29%

Downside

Reiterated

10/12/26

Biogen price target raised to $220 from $208 at BMO CapitalBiogen price target raised to $220 from $208 at BMO Capital

Chris Schott

J.P. Morgan

CHF173.15→CHF247.35

Buy

11.42%

Upside

Upgraded

10/12/26

Biogen upgraded to Overweight from Neutral at JPMorganBiogen upgraded to Overweight from Neutral at JPMorgan

Michael Yee

UBS

CHF197.88→CHF222.62

Buy

0.28%

Upside

Assigned

10/09/26

Biogen price target raised to $270 from $240 at UBSBiogen price target raised to $270 from $240 at UBS

Brian Abrahams

RBC Capital

CHF214.37→CHF211.07

Buy

-4.92%

Downside

Reiterated

10/08/26

Biogen price target lowered to $256 from $260 at RBC CapitalBiogen price target lowered to $256 from $260 at RBC Capital

Ami Fadia

Needham

CHF211.07

Buy

-4.92%

Downside

Reiterated

10/06/26

Biogen Maintained at Buy as Analyst Sees Favorable Risk-Reward Ahead of Lupus Data; $256 Price Target Reaffirmed

Andrew Tsai

Jefferies

CHF210.25

Buy

-5.29%

Downside

Reiterated

10/05/26

Analysts Are Bullish on Top Healthcare Stocks: Liquidia Technologies (LQDA), Kodiak Sciences (KOD)

Morten Herholdt

HSBC

CHF136.04→CHF144.29

Sell

-35.01%

Downside

Reiterated

09/10/26

Biogen price target raised to $175 from $165 at HSBCBiogen price target raised to $175 from $165 at HSBC

Alexandria Hammond

Wolfe Research

CHF247.35

Buy

11.42%

Upside

Upgraded

08/13/26

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (NASDAQ: APGE) and Biogen (NASDAQ: BIIB)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jason Zemansky

Bank of America Securities

CHF180.57→CHF201.18

Hold

-9.38%

Downside

Reiterated

10/22/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (NASDAQ: BIIB), Elevance Health (NYSE: ELV) and Myriad Genetics (NASDAQ: MYGN)

Phil Nadeau

TD Cowen

CHF185.51→CHF206.13

Buy

-7.15%

Downside

Reiterated

10/21/26

Biogen price target raised to $250 from $225 at TD CowenBiogen price target raised to $250 from $225 at TD Cowen

Mohit Bansal

Wells Fargo

CHF206.13→CHF255.6

Buy

15.13%

Upside

Reiterated

10/20/26

Wells Fargo Reaffirms Their Buy Rating on Biogen (BIIB)

Laura Chico

Wedbush

CHF174.79

Hold

-21.26%

Downside

Reiterated

10/19/26

Wedbush Remains a Hold on Biogen (BIIB)

Jeffrey Walch

Bernstein

CHF194.58

Buy

-12.35%

Downside

Reiterated

10/19/26

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), AbbVie (NYSE: ABBV) and Marker Therapeutics (NASDAQ: MRKR)

David Amsellem

Piper Sandler

CHF202

Buy

-9.01%

Downside

Reiterated

10/12/26

Piper Sandler Keeps Their Buy Rating on Biogen (BIIB)

Geoff Meacham

Citi

CHF177.27

Hold

-20.15%

Downside

Reiterated

10/12/26

Citi Remains a Hold on Biogen (BIIB)

Evan Seigerman

BMO Capital

CHF171.5→CHF181.39

Hold

-18.29%

Downside

Reiterated

10/12/26

Biogen price target raised to $220 from $208 at BMO CapitalBiogen price target raised to $220 from $208 at BMO Capital

Chris Schott

J.P. Morgan

CHF173.15→CHF247.35

Buy

11.42%

Upside

Upgraded

10/12/26

Biogen upgraded to Overweight from Neutral at JPMorganBiogen upgraded to Overweight from Neutral at JPMorgan

Michael Yee

UBS

CHF197.88→CHF222.62

Buy

0.28%

Upside

Assigned

10/09/26

Biogen price target raised to $270 from $240 at UBSBiogen price target raised to $270 from $240 at UBS

Brian Abrahams

RBC Capital

CHF214.37→CHF211.07

Buy

-4.92%

Downside

Reiterated

10/08/26

Biogen price target lowered to $256 from $260 at RBC CapitalBiogen price target lowered to $256 from $260 at RBC Capital

Ami Fadia

Needham

CHF211.07

Buy

-4.92%

Downside

Reiterated

10/06/26

Biogen Maintained at Buy as Analyst Sees Favorable Risk-Reward Ahead of Lupus Data; $256 Price Target Reaffirmed

Andrew Tsai

Jefferies

CHF210.25

Buy

-5.29%

Downside

Reiterated

10/05/26

Analysts Are Bullish on Top Healthcare Stocks: Liquidia Technologies (LQDA), Kodiak Sciences (KOD)

Morten Herholdt

HSBC

CHF136.04→CHF144.29

Sell

-35.01%

Downside

Reiterated

09/10/26

Biogen price target raised to $175 from $165 at HSBCBiogen price target raised to $175 from $165 at HSBC

Alexandria Hammond

Wolfe Research

CHF247.35

Buy

11.42%

Upside

Upgraded

08/13/26

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (NASDAQ: APGE) and Biogen (NASDAQ: BIIB)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

PTGXProtagonist Therapeutics

SIBNSI-Bone

IMUXImmunic

MDWDMediwound

HROWHarrow Health

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biogen

3 Months

Salveen RichterGoldman Sachs

Success Rate

16/27 ratings generated profit

Average Return

+2.08%

Copying Salveen Richter's trades and holding each position for 3 Months would result in 59.26% of your transactions generating a profit, with an average return of +2.08% per trade.

1 Year

Myles MinterWilliam Blair

Success Rate

16/23 ratings generated profit

Average Return

+20.63%

Copying Myles Minter's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +20.63% per trade.

2 Years

Myles MinterWilliam Blair

Success Rate

15/23 ratings generated profit

Average Return

+21.97%

Copying Myles Minter's trades and holding each position for 2 Years would result in 65.22% of your transactions generating a profit, with an average return of +21.97% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIIB Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BIIB has received 20 Buy Ratings, 8 Hold Ratings, and 1 Sell Ratings. BIIB average Analyst price target in the past 3 months is 202.08.

Each month's total comprises the sum of three months' worth of ratings.

BIIB Financial Forecast

BIIB Earnings Forecast

Next quarter’s earnings estimate for BIIB is CHF1.62 with a range of CHF1.18 to CHF1.90. The previous quarter’s EPS was CHF2.96. BIIB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Sales Forecast

Next quarter’s sales forecast for BIIB is CHF2.16B with a range of CHF2.05B to CHF2.26B. The previous quarter’s sales results were CHF2.15B. BIIB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Stock Forecast FAQ

What is CH:BIIB’s average 12-month price target, according to analysts?

Based on analyst ratings, Biogen’s 12-month average price target is 202.08.

What is CH:BIIB’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for CH:BIIB, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Biogen a Buy, Sell or Hold?

Biogen has a consensus rating of Moderate Buy, which is based on 16 buy ratings, 6 hold ratings and 1 sell ratings.

What is Biogen’s share price target?

The average share price target for Biogen is 202.08. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF255.60 ,and the lowest forecast is CHF144.29. The average share price target represents -8.97% Decrease from the current price of CHF222.

What do analysts say about Biogen?

Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of Biogen?

To buy shares of CH:BIIB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Biogen (BIIB) Stock Forecast & Price Target

BIIB Analyst Ratings

BIIB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Biogen

BIIB Analyst Recommendation Trends

BIIB Financial Forecast

BIIB Earnings Forecast

BIIB Sales Forecast

BIIB Stock Forecast FAQ

Detailed List of Analyst Forecasts